A Vaccine (CIMAvax-EGF) for the Prevention of Lung Cancer Development or Recurrence

Inclusion Criteria: * Confirmed no evidence of cancer on computed tomography (CT) scan within 6 months prior to starting treatment * Have an Eastern Cooperative Oncology Group (ECOG) performance status of =\< 2 * Patients must have platelets \>= 100 x 10\^9/L * Participants of child-bearing potential must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry * Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately * Participant must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure * PATIENTS AT HIGH-RISK FOR LUNG CANCER COHORT ONLY (COHORT A) * Must have documented at least one risk factor for lung cancer which includes: * Moderate to severe chronic obstructive pulmonary disease (COPD) defined as FEV1/FVC ratio \<=75% * Positive family history of lung cancer defined as a first degree relative * Low body mass index (BMI) * History of pneumonia within the last 5 years prior to enrollment * Occupational exposure such as asbestos, radon and any other that investigator would deem high risk * Must have quit smoking =\< 15 years ago or be a current smoker * Must have at least 30 pack year smoking history * Must have documented pu…